Abstract | INTRODUCTION: METHODS:
Nelarabine (35 mg/kg, approximately 700 mg/m2) was administered over 1 h through a surgically implanted central venous catheter to four nonhuman primates. Blood (four animals) and ventricular CSF (three animals) samples were obtained at intervals for 24 h for determination of nelarabine concentrations, which were measured by HPLC-mass spectrometry. RESULTS: The nelarabine plasma AUC (median+/-s.d.) was 2,820+/-1,140 microM min and the ara-G plasma AUC was 20,000+/-8,100 microM min. The terminal half-life of nelarabine in plasma was 25+/-5.2 min and clearance was 42+/-61 ml/min/kg. The terminal half-life of ara-G in plasma was 182+/-45 min. In CSF the terminal half-life of nelarabine was 77+/-28 min and of ara-G was 232+/-79 min. The AUCcsf:AUCplasma was 29+/-11% for nelarabine and 23+/-12% for ara-G. CONCLUSION:
|
Authors | Stacey L Berg, Claudia Brueckner, Jed G Nuchtern, Robert Dauser, Leticia McGuffey, Susan M Blaney |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 59
Issue 6
Pg. 743-7
(May 2007)
ISSN: 0344-5704 [Print] Germany |
PMID | 16953392
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Arabinonucleosides
- Prodrugs
- 9-arabinofuranosylguanine
- nelarabine
|
Topics |
- Animals
- Antineoplastic Agents
(blood, cerebrospinal fluid)
- Arabinonucleosides
(blood, cerebrospinal fluid)
- Chromatography, High Pressure Liquid
- Macaca mulatta
- Male
- Mass Spectrometry
- Prodrugs
(pharmacokinetics)
|